CEL-SCI Multikine Phase 3 Data Published
Analysis based on 6 articles · First reported Jul 30, 2026 · Last updated Aug 04, 2026
The publication in a leading peer-reviewed journal enhances the credibility of CEL-SCI Corporation's clinical data and supports the scientific foundation for its Confirmatory Registration Study, potentially increasing investor confidence and the company's valuation. Positive clinical results and regulatory progress could attract partnerships and funding, positively impacting CEL-SCI Corporation's stock price and the broader biotech sector focused on immunotherapies.
CEL-SCI Corporation Corporation announced that its Phase 3 IT-MATTERS clinical trial data for Multikine, an investigational neoadjuvant immunotherapy for head and neck cancer, has been accepted for publication in the peer-reviewed journal Oral Oncology. The study demonstrates a significant overall survival benefit in patients with low or zero PD-L1 expression and no lymph node involvement, showing a 73.4% five-year survival rate versus 45.8% for standard of care alone (hazard ratio 0.34). The publication validates the biomarker strategy for patient selection in CEL-SCI Corporation's upcoming global 212-patient Confirmatory Registration Study, which is designed to confirm these results. Multikine is being developed for an underserved patient population with limited treatment options.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard